fig4
![MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression](https://image.oaes.cc/110f735f-64b9-49ee-9793-5d4b2035bc3f/3433.fig.4.jpg)
Figure 4. MMTV-Neu cells exhibit insensitivity to JAK inhibitors compared to other murine mammary cancer cell lines. A: immunoblot analysis of MMTV-Neu cells treated with or without trametinib (50 nM; MEKi) and/or Ruxolitinib (1 µM; Rux) for 48 h prior to lysis; B: immunoblot analysis of E0771, EMT6, and 4T1 cells treated as in A. MEKi: MEK inhibition